Manufacturer
GLAXO WELLCOME INC
Contents
Zidovudine
Indication
Reduction of maternal-foetal transmission rate of HIV. Syr: In combination w/ other antiretroviral agents for treatment of HIV. IV infusion: Short-term management of serious manifestations of HIV infection in patients w/ AIDS who are unable to take oral formulations.
Instruction
In combination w/ other antiretrovirals Adult & adolescent at least 30 kg 250 or 300 mg bd. Childn at least 9 kg & <30 kg 9 mg/kg bd, not to exceed 300 mg bd, at least 4 kg & <9 kg 12 mg/kg bd.
Drug interaction
Decreased metabolism rate by atovaquone. Reduced absorption by clarithromycin. Increased Cmax w/ lamivudine. Lowered phenytoin blood levels. Increased mean t½ & AUC by probenecid. Decreased AUC w/ rifampicin. Inhibited intracellular phosphorylation of stavudine. Altered metabolism by aspirin, codeine, morphine, methadone, indomethacin, ketoprofen, naproxen, oxazepam, lorazepam, cimetidine, clofibrate, dapsone & isoprinosine. Increased risk of adverse reactions w/ potentially nephrotoxic or myelosuppressive drugs.
Malaysia
